Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Forlano, Roberta; Sivakumar, Mathuri; Mullish, Benjamin H.; Manousou, Pinelopi

doi:10.3390/ijms23158307

Cited by 12 publications

(9 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The gut microbiota can also be altered using antibiotics. 74 For example, coadministration of polymyxin B and neomycin was found to prevent hepatic lipid accumulation in mice on a high-fructose diet. 75 Vancomycin, metronidazole ampicillin, rifaximin, and solithromycin are other antibiotics that have been used in preclinical and clinical studies.…”

Section: Gut Microbiotamentioning

confidence: 99%

See 1 more Smart Citation

Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions

Eeda,

Patil,

Joshi

et al. 2024

Hepatology Research

View full text Add to dashboard Cite

Metabolic (dysfunction) associated steatotic liver disease (MASLD) formerly known as non‐alcoholic fatty liver disease (NAFLD) is a growing global health concern with no approved pharmacological treatments. At the same time, there are no standard methods to definitively screen for the presence of MASLD because of its progressive nature and symptomatic commonality with other disorders. Recent advances in molecular understanding of MASLD pathophysiology have intensified research on development of new drug molecules, repurposing of existing drugs approved for other indications, and an educated use of dietary supplements for its treatment and prophylaxis. This review focused on depicting the latest advancements in MASLD research related to small molecule development for prophylaxis or treatment and diagnosis, with emphasis on mechanistic basis at the molecular level.This article is protected by copyright. All rights reserved.

show abstract

Section: Gut Microbiotamentioning

confidence: 99%

“…Synbiotic treatments combine the probiotic and prebiotic in a single product. The gut microbiota can also be altered using antibiotics 74 . For example, coadministration of polymyxin B and neomycin was found to prevent hepatic lipid accumulation in mice on a high‐fructose diet 75 .…”

Section: Emerging Therapies For Masldmentioning

confidence: 99%

Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions

Eeda,

Patil,

Joshi

et al. 2024

Hepatology Research

View full text Add to dashboard Cite

show abstract

“…, no FMT)[ 148 ]. There have also been several human clinical trials but with mixed outcomes, with some achieving a significant reduction in proinflammatory cytokines and improved gut barrier function and others not responding to therapy[ 149 , 150 ]. Future experiments should address the question of who qualifies as a healthy donor, how should we deal with the variation in gut microbial diversity among the recipients, and how best to package the product for better acceptability.…”

Section: Therapeutic Approachesmentioning

confidence: 99%

Microbiome-liver crosstalk: A multihit therapeutic target for liver disease

Kirundi¹,

Moghadamrad²,

Urbaniak³

2023

World J Gastroenterol

View full text Add to dashboard Cite

Liver disease has become a leading cause of death, particularly in the West, where it is attributed to more than two million deaths annually. The correlation between gut microbiota and liver disease is still not fully understood. However, it is well known that gut dysbiosis accompanied by a leaky gut causes an increase in lipopolysaccharides in circulation, which in turn evoke massive hepatic inflammation promoting liver cirrhosis. Microbial dysbiosis also leads to poor bile acid metabolism and low short-chain fatty acids, all of which exacerbate the inflammatory response of liver cells. Gut microbial homeostasis is maintained through intricate processes that ensure that commensal microbes adapt to the low oxygen potential of the gut and that they rapidly occupy all the intestinal niches, thus outcompeting any potential pathogens for available nutrients. The crosstalk between the gut microbiota and its metabolites also guarantee an intact gut barrier. These processes that protect against destabilization of gut microbes by potential entry of pathogenic bacteria are collectively called colonization resistance and are equally essential for liver health. In this review, we shall investigate how the mechanisms of colonization resistance influence the liver in health and disease and the microbial-liver crosstalk potential as therapeutic target areas.

show abstract

“…Intestinal inflammation and dysfunction of intestinal lipid and bile acid absorption, epithelial cell permeability and the microbiome affect liver function and contribute to NAFLD progression. The relationship between gut microbiota and potential therapeutic targets has been recently discussed in depth elsewhere[ 110 , 111 ]; thus, we only focus on other aspects of the gut-liver axis.…”

Section: Potential Targets Outside the Livermentioning

confidence: 99%

Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies

Wang¹,

Zhang²,

Guan³

2023

World J Gastroenterol

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD), a leading chronic disease worldwide, affects approximately a quarter of the global population. Nonalcoholic steatohepatitis (NASH) is an advanced form of NAFLD and is more likely to progress to liver fibrosis than simple steatosis. NASH is also identified as the most rapidly growing cause of hepatocellular carcinoma. Although in the past decade, several phase II/III clinical trials have shown promising results in the use of novel drugs targeting lipid synthase, farnesoid X receptor signaling, peroxisome proliferator-activated receptor signaling, hepatocellular injury, and inflammatory signaling, proven pharmaceutical agents to treat NASH are still lacking. Thus, continuous exploration of the mechanism underlying the pathogenesis of NAFLD and the identification of novel therapeutic targets remain urgent tasks in the field. In the current review, we summarize studies reported in recent years that not only provide new insights into the mechanisms of NAFLD development but also explore the possibility of treating NAFLD by targeting newly identified signaling pathways. We also discuss evidence focusing on the intrahepatic targets involved in the pathogenesis of NAFLD as well as extrahepatic targets affecting liver metabolism and function.

show abstract

Gut Microbiota—A Future Therapeutic Target for People with Non-Alcoholic Fatty Liver Disease: A Systematic Review

Cited by 12 publications

References 95 publications

Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions

Advancements in metabolic‐associated steatotic liver disease research: Diagnostics, small molecule developments, and future directions

Microbiome-liver crosstalk: A multihit therapeutic target for liver disease

Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies

Contact Info

Product

Resources

About